Pacific Biosciences is trading 5.2% down at $1.28 as the broader market and biotechnology sector weaken.
- On September 1, 2026, risk-off sentiment reflects Middle East tensions, higher oil prices, rising bond yields and renewed inflation concerns, pressuring volatile growth-oriented biotech shares.
- The XBI biotech ETF is down 4.24%, and major U.S. indexes are also lower.
- No new company-specific announcement was identified for September 1.